Back to Search
Start Over
The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility
- Source :
- Retrovirology, Retrovirology, vol 13, iss 1
- Publication Year :
- 2016
- Publisher :
- Springer Science and Business Media LLC, 2016.
-
Abstract
- Background The p6 region of the HIV-1 structural precursor polyprotein, Gag, contains two motifs, P7TAP11 and L35YPLXSL41, designated as late (L) domain-1 and -2, respectively. These motifs bind the ESCRT-I factor Tsg101 and the ESCRT adaptor Alix, respectively, and are critical for efficient budding of virus particles from the plasma membrane. L domain-2 is thought to be functionally redundant to PTAP. To identify possible other functions of L domain-2, we examined this motif in dominant viruses that emerged in a group of 14 women who had detectable levels of HIV-1 in both plasma and genital tract despite a history of current or previous antiretroviral therapy. Results Remarkably, variants possessing mutations or rare polymorphisms in the highly conserved L domain-2 were identified in seven of these women. A mutation in a conserved residue (S40A) that does not reduce Gag interaction with Alix and therefore did not reduce budding efficiency was further investigated. This mutation causes a simultaneous change in the Pol reading frame but exhibits little deficiency in Gag processing and virion maturation. Whether introduced into the HIV-1 NL4-3 strain genome or a model protease (PR) precursor, S40A reduced production of mature PR. This same mutation also led to high level detection of two extended forms of PR that were fairly stable compared to the WT in the presence of IDV at various concentrations; one of the extended forms was effective in trans processing even at micromolar IDV. Conclusions Our results indicate that L domain-2, considered redundant in vitro, can undergo mutations in vivo that significantly alter PR function. These may contribute fitness benefits in both the absence and presence of PR inhibitor. Electronic supplementary material The online version of this article (doi:10.1186/s12977-016-0298-1) contains supplementary material, which is available to authorized users.
- Subjects :
- 0301 basic medicine
medicine.medical_treatment
HIV Infections
Virus Replication
Reproductive Tract Infections
gag Gene Products, Human Immunodeficiency Virus
HIV Protease
Antiretroviral Therapy, Highly Active
2.1 Biological and endogenous factors
TSG101
HIV Protease Inhibitor
Aetiology
Virus Release
3. Good health
Infectious Diseases
HIV/AIDS
Female
Infection
Human Immunodeficiency Virus
Clinical Sciences
030106 microbiology
Antiretroviral Therapy
Biology
Virus
ESCRT
03 medical and health sciences
Genetic
Virology
Genetics
medicine
Humans
Highly Active
Polymorphism
gag Gene Products
Polymorphism, Genetic
Protease
Research
HEK 293 cells
HIV Gag
HIV Protease Inhibitors
Protease inhibitors
HEK293 Cells
030104 developmental biology
Viral replication
Mutation
Late domain
HIV-1
Anti-retroviral drugs
Trans-acting
Transcription Factors
Subjects
Details
- ISSN :
- 17424690
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Retrovirology
- Accession number :
- edsair.doi.dedup.....2d6b70353fb0ac547d2900877265affc
- Full Text :
- https://doi.org/10.1186/s12977-016-0298-1